Corvus' soquelitinib shows promise in oncology & autoimmune fields, with Phase 3 PTCL data as a key catalyst. Click here to ...

The three assets are a pair of anti-TIGIT antibodies – domvanalimab (AB154) and AB308 – along with adenosine A2a/A2b receptor antagonist etrumadenant and small-molecule CD73 inhibitor ...

However, none of the rival programmes have advanced too far in clinical development, and a trial of one regimen – the combination of AZ's A2A drug AZD4635 and a CD73 blocking agent called ...

Vision begins in the retina at the rod and cone photoreceptors, which are sensory neurons with specialized visual pigments for capturing light quanta. Most mammals have one type of rod and two ...

Hypothalamus participates in systemic metabolic processes, while high calorie intake increases immune activation in the central nervous system. Here the authors show that reduced regulatory T ...

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate ...